COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica and Meta further advance AI glasses category with new products revealed at Meta Connect
24/09/2026
EssilorLuxottica and Meta further advance AI glasses category with new products revealed at Meta Connect The two companies introduce new line of audio AI glasses and next generation of Ray-Ban Meta, the world’s leading [...]
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
24/09/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
23/09/2026
Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics [...]
Zymeworks Completes Acquisition of Theravance Biopharma
23/09/2026
Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a [...]
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
23/09/2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
23/09/2026
NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Park Dental Partners Expands Arizona Presence with Addition of Sapphire Dental Care
23/09/2026
MINNEAPOLIS, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, announced that the single practice Sapphire Dental Care and its three (3) doctors joined [...]
CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
23/09/2026
The Vision Centre Brings Industry Leading Innovation to Accelerate Breakthroughs in Eye Care SAN RAMON, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today reinforced its commitment to [...]
Precision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026
23/09/2026
LITTLETON, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
23/09/2026
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson’s disease with no major clinical advances in 50+ years Meet with Serina’s CEO Steven Ledger [...]
Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions
23/09/2026
Silver Spring, MD, Sept. 23, 2026 (GLOBE NEWSWIRE) -- A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA- [...]
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
23/09/2026
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial [...]
Teva Releases Q3 2026 Aide Memoire
23/09/2026
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on [...]
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
23/09/2026
Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) [...]
Regina Skin Medical Introduces Preventive Medical Beauty Methodology Following Long-Term Skin Metabolism Studies
23/09/2026
HONG KONG, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regina Skin Medical has announced the introduction of a new preventive medical beauty framework designed to address the root causes of chronic skin pigmentation, [...]
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option
23/09/2026
Lyrfigtu demonstrated a confirmed ORR of 46% and mDOR of 11.8 months, with a predictable and manageable safety profile CCA, also known as bile duct cancer, is diagnosed in about 8,000 people in the U.S. each year FORT [...]
Ozari Health Named Best Place to Buy Compounded Tirzepatide Online for 2026
23/09/2026
The New York telehealth platform's compounded tirzepatide program, priced at $125 per month all-in with two publicly named US-licensed 503A compounding pharmacies, leads a new MedicalResearch.com comparison of the best [...]
CROSSJECT et la BARDA consolident le plan de développement pédiatrique de ZEPIZURE® selon les attentes de la FDA avec un financement renforcé jusqu’en 2030
23/09/2026
CROSSJECT et la BARDA ont consolidé le plan de développement clinique de ZEPIZURE® pour l’indication pédiatrique, conformément aux recommandations de la FDA Un financement supplémentaire non dilutif de 4,7 millions de [...]
CROSSJECT and BARDA align ZEPIZURE®’s Pediatric development plan with FDA including funding through 2030
23/09/2026
CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE®, in alignment with the FDA guidance $4.7 million in additional, non-dilutive funding, to cover the planned [...]

Pages